ABT vs MDT
Abbott Laboratories and Medtronic, side by side.
Prices and company dataas of yesterday's close
- ABTKeep2.3%
Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%).
- MDTSell some2.8%
Medtronic pays a 2.8% dividend that it has raised for 50 years in a row, but the stock rose 15% over the past month, more than other medical device makers (up 8.3%).
Percent return
- ABT−11.81%
- MDT+10.04%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: ABT $174B, MDT $112B.
- Sales growth, 1 yr: ABT +10%, MDT +9.8%. ABT is ahead.
- Price for $1 of next year's profit: ABT $19, MDT $17. MDT is ahead.
- Profit per $1 of sales: ABT 16¢, MDT 20¢. MDT is ahead.
- Cash minus debt: ABT −$27.1B, MDT −$19.2B. MDT is ahead.
- Price change, 1 yr: ABT −12%, MDT +10%. MDT is ahead. S&P 500 +12%.
- How much the price swings: ABT 30%, MDT 28%. MDT is ahead.
| Measure | ABTAbbott Laboratories | MDTMedtronic |
|---|---|---|
| Price and returns | ||
| Price | $109.35 | $101.64 |
| Today | −1.00% | Best in this row: +0.04% |
| 1 month | +10.40% | Best in this row: +14.84% |
| 3 months | +0.28% | Best in this row: +13.00% |
| This year | −10.60% | Best in this row: +8.49% |
| 1 year | −11.81% | Best in this row: +10.04% |
| 5 years | −5.13% | Best in this row: −0.29% |
| From 52-week high | −14.2% | −3.2% |
| How much it swings (90 days) | 30% | Best in this row: 28% |
| Valuation | ||
| Market value | $174B | $112B |
| Price vs last year's earnings | 32.3× | Best in this row: 23.5× |
| Price vs next year's expected earnings | 18.8× | Best in this row: 16.9× |
| Price vs earnings, adjusted for growth | 1.65× | Best in this row: 1.62× |
| Price to sales | 4.0× | Best in this row: 3.3× |
| Price vs cash it brings in | 28.2× | Best in this row: 20.3× |
| Company value vs operating profit | 19.0× | Best in this row: 13.8× |
| Price vs earnings, against its own past (0 = cheapest) | – | 100 |
| Growth | ||
| Revenue growth, 1 year | Best in this row: +10.0% | +9.8% |
| Revenue growth a year, last 3 years | +0.5% | Best in this row: +5.2% |
| Earnings per share growth, last year | −53.4% | Best in this row: +3.2% |
| Earnings per share growth expected next year | Best in this row: +7.6% | +7.0% |
| Profitability | ||
| Kept from sales after making the product | 57.2% | Best in this row: 65.3% |
| Kept as operating profit | 15.7% | Best in this row: 20.1% |
| Kept as final profit | 9.7% | Best in this row: 13.9% |
| Kept as spare cash | 14.0% | Best in this row: 16.3% |
| Profit on shareholders' money | 9.1% | Best in this row: 10.7% |
| Profit on all money put in | 6.9% | Best in this row: 8.6% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$27.1B | Best in this row: −$19.2B |
| Debt for each $1 of shareholders' money | 0.61× | Best in this row: 0.55× |
| Short-term assets per $1 of bills due | 1.45× | Best in this row: 2.07× |
| Dividend yield | 2.29% | Best in this row: 2.83% |
| Share of profit paid as dividends | 94% | Best in this row: 71% |
| Our readPro | ||
| Our call | Keep | Sell some |
| Why | Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%). | Medtronic pays a 2.8% dividend that it has raised for 50 years in a row, but the stock rose 15% over the past month, more than other medical device makers (up 8.3%). |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | 57 | Best in this row: 62 |
| Our value score | 82 | Best in this row: 87 |
| Our growth score | 33 | Best in this row: 48 |
| Our quality score | Best in this row: 68 | 63 |
| Our price trend score | Best in this row: 63 | 61 |
| Earnings and analysts | ||
| Next earnings | – | Nov 24BMOin 12 days |
| Analyst consensus | Buy | Buy |
| To average analyst target | Best in this row: +11.5% | +1.5% |
| Average analyst target | $121.94 | $103.19 |
| Analysts rating it a buy | Best in this row: 82% | 67% |
| Buy ratings added, 3 months | Best in this row: +2 | +1 |
| Analysts covering | 17 | 19 |
ABT: more analyst upside
Our pick of these: Abbott Laboratories
+11.5% to the average analyst target, vs +1.5%
ABT +11.5%, MDT +1.5%.82% of analysts rate it a buy, vs 67%
ABT 82%, MDT 67%.Where it loses: MDT has wider profit margins, 20.1% vs 15.7%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.